drugset / Trial / NCT05773950

Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

NCT05773950

Enrolling by invitation 144 enrolled Samsung Medical Center
RandomizedParallel-groupQuadruple-blindPrevention

Summary

As a preventive for postoperative nausea and vomiting in patients undergoing laparoscopic gynecological surgery, the investigators shall investigate the efficacy of the triple therapy of dexamethasone, palonosetron, and fosaprepitant comparing to dual therapy of dexamethasone and palonosetron.

Timeline

Start
2023-08-18
Primary completion
2025-12
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosaprepitant Other / unclassified 150 mg

Indications

No indication recorded.